ADTX

Aditxt, Inc.

Company Overview

Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.

SectorHealthcare
IndustryBiotechnology
Market Cap$399.2K
Last DividendNone
Employees26
CEOJeffrey Busch

Valuation

Current Price$0
Fair Value?$000.00
Valuation?No valuation
Current PE ?N/Aⓘ
Hist. PE ?N/Aⓘ
EPS (TTM) ?-31153.41
Forward EPS Growth ?—
Historical Growth ?60.28%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro

Price?

EPS?

Revenue?

Equity?

Pro

Available on the Pro plan

Free Cash Flow?

Pro

Available on the Pro plan

Long Term Debt?

Pro

Available on the Pro plan

Net Profit?

Pro

Available on the Pro plan

Shares Outstanding?

Pro

Available on the Pro plan

Last updated: 10/23/2026, 10:58:51 PM